Latest filing published 02 Jul 2021 for ImmunoGen, Inc., €18k.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Thomas Ryll: trading record in brief
Thomas Ryll (senior executive) discloses dealings in ImmunoGen, Inc. to SEC (Form 4). In total, 7 filings cover trades dated from 21 February 2018 to 30 June 2021.
The open-market record consists of 3 sales worth €234k, with no purchase. Besides market trades, the filings include 4 share grants.
The record was last updated on 2 July 2021 with a share grant (€18k) in ImmunoGen, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Thomas Ryll
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 3,849 shares@ US$5.52100.0% of flowCommon StockSEC:0001179110-21-007314:0
1 of 1 declaration
